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studyquestion: Can we identify compound(s) with reported phosphodiesterase inhibitor (PDEI) activity that could be added to human
spermatozoa in vitro to enhance their motility without compromising other sperm functions?
summaryanswer:We have identiﬁed several compounds that produce robust and effective stimulation of sperm motility and, import-
antly, have a positive response on patient samples.
what is known already: For.20 years, the use of non-selective PDEIs, such as pentoxifylline, has been known to inﬂuence themo-
tility of human spermatozoa; however, conﬂicting results have been obtained. It is now clear that human sperm express several different phos-
phodiesterases and these are compartmentalized at different regions of the cells. By using type-speciﬁc PDEIs, differential modulation of sperm
motility may be achieved without adversely affecting other functions such as the acrosome reaction (AR).
study design, size, duration: This was a basic medical research study examining sperm samples from normozoospermic donors
and subfertile patients attending the Assisted Conception Unit (ACU), Ninewells Hospital Dundee for diagnostic semen analysis, IVF and ICSI.
Phase 1 screened 43 commercially available compounds with reported PDEI activity to identify lead compounds that stimulate sperm motility.
Samples were exposed (20 min) to three concentrations (1, 10 and 100 mM) of compound, and selected candidates (n ¼ 6) progressed to
Phase 2, which provided a more comprehensive assessment using a battery of in vitro sperm function tests.
participants/materials, setting, methods: All healthy donors and subfertile patients were recruited at the Medical Re-
search Institute,University ofDundee andACU,NinewellsHospitalDundee (ethical approval 08/S1402/6). In Phase 1, poormotility cells recov-
ered from the 40% interface of the discontinuous density gradientwere used as surrogates for patient samples. Pooled samples from three to four
different donors were utilized in order to reduce variability and increase the number of cells available for simultaneous examination of multiple
compounds. During Phase 2 testing, semen samples from 23 patients attending for either routine diagnostic andrology assessment or IVF/ICSI
were prepared and exposed to selected compounds. Additionally, 48 aliquots of prepared samples, surplus to clinical use, were examined from
IVF (n ¼ 32) and ICSI (n ¼ 16) patients to further determine the effects of selected compounds under clinical conditions of treatment. Effects of
compounds on sperm motility were assessed by computer-assisted sperm analysis. A modiﬁed Kremer test using methyl cellulose was used to
assess sperm functional ability to penetrate into viscous media. Sperm acrosome integrity and induction of apoptosis were assessed using the
acrosomal content marker PSA-FITC and annexin V kit, respectively.
main results and the role of chance: In Phase 1, six compounds were found to have a strong effect on poor motility samples
with a magnitude of response of ≥60% increase in percentage total motility. Under capacitating and non-capacitating conditions, these
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compounds signiﬁcantly (P ≤ 0.05) increased the percentage of total and progressive motility. Furthermore, these compounds enhanced pene-
tration into a cervical mucus substitute (P ≤ 0.05). Finally, theARwas not signiﬁcantly induced and these compounds did not signiﬁcantly increase
the externalization of phosphatidylserine (P ¼ 0.6, respectively). In general, the six compounds maintained the stimulation of motility over long
periods of time (180 min) and their effects were still observed after their removal. In examinations of clinical samples, there was a general obser-
vation of a more signiﬁcant stimulation of spermmotility in samples with lower baseline motility. In ICSI samples, compounds #26, #37 and #38
were themost effective at signiﬁcantly increasing total motility (88, 81 and 79%of samples, respectively) and progressivemotility (94, 93 and 81%
of samples, respectively). In conclusion, using a two-phased drug discovery screening approach including the examinationof clinical samples, 3/43
compounds were identiﬁed as promising candidates for further study.
limitations, reasons for caution: This is an in vitro study and caution must be taken when extrapolating the results. Data for
patients were from one assessment and thus the robustness of responses needs to be established. The n values for ICSI samples were relatively
small.
wider implications of the findings: We have systematically screened and identiﬁed several compounds that have robust and
effective stimulation (i.e. functional signiﬁcance with longevity and no toxicity) of total and progressive motility under clinical conditions of treat-
ment. These compounds could be clinical candidates with possibilities in terms of assisted reproductive technology options for current or future
patients affected by asthenozoospermia or oligoasthenozoospermia.
study funding/competing interest(s): This study was funded primarily by the MRC (DPFS) but with additional funding from
theWellcome Trust, Tenovus (Scotland), University of Dundee,NHSTayside and Scottish Enterprise. The authors have no competing interests.
A patent (#WO2013054111A1) has been published containing some of the information presented in this manuscript.
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Introduction
Sperm dysfunction has long been acknowledged as the single most
common cause of infertility (Hull et al., 1985; Irvine, 1998), yet there is
currently no drug a man can take to signiﬁcantly improve his fertility.
The only option is assisted reproductive technology (ART) which
usually consists of a graduation of treatment depending on severity, i.e.
intrauterine insemination (IUI) formild, in vitro fertilization (IVF) formod-
erate and intra-cytoplasmic sperm injection (ICSI) for men with severe,
sperm dysfunction (Barratt et al., 2011). A primary manifestation of
spermdysfunction is poormotilitywhichnegatively impacts on successful
ART (PublicoverandBarratt, 2011; Vander Steeg et al., 2011; Tomlinson
et al., 2013). Before ICSI, the various strategies to improve the IVF fertil-
ization rate by chemical stimulation of spermatozoa primarily involved
treatment with non-speciﬁc inhibitors of phosphodiesterases (PDEIs,
e.g. pentoxifylline (PTX)), a family of related phosphohydrolases that se-
lectively catalyse hydrolysis of the 3′ cyclic phosphate bonds of cAMP or
cGMP.A landmark studydemonstrated a signiﬁcant enhancement of fer-
tilization rates when using PTX (Yovich et al., 1990) and 77 pregnancies
were achieved (Yovich, 1993). Two IUI studies later reported higher
pregnancy rates following sperm stimulation with PTX combined with
IUI but the data were not part of a controlled study (Negri et al., 1996;
Stone et al., 1999). However, the results using PTX have been inconsist-
ent. For example, Tournaye et al. showed a lower fertilization rate in vitro
following PTX treatment, probably due to the nature of the patients
selected (moderate male factor infertility versus previous unsuccessful
IVF treatment) and/or the protocols of PTX addition (Tournaye et al.,
1994). Following development of ICSI, which has nowbecome the treat-
ment of choice for severe male factor infertility, the concept of sperm
stimulation for IVF/IUI has fallen from grace.
Previously published in vitro studies using PTX provide explanations
concerning its potential limitations. For example, Tesarik et al. examined
the use of PTX (ﬁnal concentration 1 mg/ml) on in vitro spermmotility in
14 normal men and 25 men with asthenozoospermia. Consistent with
other authors, PTX did not affect the percentage of motile cells but sig-
niﬁcantly increased velocity. This occurred in all the men with normal
semen analysis and in themajority ofmen (21/25)with asthenozoosper-
mia. In the latter, all men showed an increase in hyperactivation.
However, in studies using PTX, a signiﬁcant disadvantage has been the
premature stimulation of the acrosome reaction (AR) (Tesarik et al.,
1992; Yovich, 1993; Ford et al., 1994). This has discouraged further
studies on the modulation of cAMP for clinical applications.
It is now clear that there are multiple forms of phosphodiesterases
(PDEs) with different kinetic and regulatory properties, classiﬁed into 11
different families and comprising 21 different gene products. Indeed,
there are estimated to be well over 100 mRNA products, as well as
multiple proteins transcribed from these genes, due to alternative tran-
scription start sites and splicing of precursor molecules (Francis et al.,
2011). Spermatozoa contain several different PDEs, and the regulation
of intracellular cAMP and cGMP is therefore largely speciﬁed by the
exact nature and localization of the expressed PDEs (Leﬁe`vre et al.,
2000; Leﬁe`vre et al., 2002). Surprisingly, in view of the plethora of existing
and new-generationPDEIs (Francis et al., 2011), there are very few studies
examining the inhibition of speciﬁc PDEs in human sperm. Fisch et al.,
(1998) examined the biological activity of PDE-1 and PDE-4 in the
sperm of 30 subfertile men. PDE-4 inhibition (via Rolipram) selectively
increased the percentage of motile cells at 2 and 24 h of incubation, with
themost signiﬁcant effects noted in those sampleswith the lowest concen-
tration of motile cells. PDE-1 inhibitors (for example, 8-MeO-IBMX) se-
lectively activated AR, but this was not the case with inhibition of PDE-4.
The data on the role of PDE-5 are controversial, probably because
PDE-5 represents only a very small fraction of the PDE activity (Leﬁe`vre
etal., 2000).Conﬂictingbiological effectshavebeenobservedusingPDE-5-
speciﬁc inhibitors, sildenaﬁl and tadalaﬁl, in vivo (Sousa et al., 2014; Yang
et al., 2014). Induction of the AR (presumably due to an increase, above
a critical threshold, of cGMP) is frequently reported (Glenn et al., 2007).
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In an attempt to discover novel therapeutics for male factor subferti-
lity, the ﬁrstobjectiveof an effectivedrugdiscoveryprogrammewouldbe
to identify (or develop) key compounds that stimulate sperm motility
without compromising their fertilizing capacity, e.g. by causingpremature
stimulation of AR. The clinical objective was to identify compounds that
increase the number of functional sperm in the vicinity of the oocyte,
based on the hypothesis that this increase would lead to a higher
chance of fertilization, thus achieving an increase in live birth rate (see
Publicover and Barratt, 2011). If achieved, this would also increase the
availability of fertility treatments to a global population, i.e. by using IUI
instead of IVF and by making cost-effective IUI available to a much
wider patient population. There is signiﬁcant data to support this
concept.A large numberof studies demonstrate a signiﬁcant relationship
between conception in vivo and the number/concentration of motile
sperm and/or percentage motile cells in subfertile couples (reviewed
in Tomlinson et al., 1999, 2013). Indeed, the same applies in donor in-
semination. Perhaps, the most comprehensive data are from CECOS
(Centres d’e´tude et de conservation des œufs et du sperme humains)
that demonstrates an almost doubling of success rates (13 versus
7%) per cycle of treatment when the number of motile sperm in
the straws for insemination was 5–10 million rather than ,5 million
(David et al., 1980). For IUI, there is a signiﬁcant relationship between
conception and number/concentration ofmotile spermand/or the per-
centage of motile cells in the semen used for insemination. For example,
Horvath et al.presented a linear relationship between totalmotile sperm
in post-preparation samples and conception rates (Horvath et al., 1989).
Experiments in natural conception, IUI and IVF also consistently demon-
strate that the most signiﬁcant clinical relationship is observed at the
lower ends of the spectrum, e.g. with lower numbers of motile cells/
lowprogression (Publicover and Barratt, 2011). For example, Hargreave
et al., when assessing natural conception, suggested that a doubling of the
motile sperm concentration from 2 to 4 million/ml results in a 2.5-fold
increase in pregnancy rates (adapted from Comhaire, 2000; Publicover
and Barratt, 2011), yet at higher sperm concentrations the positive
effect was relatively small. Importantly for this strategy, by increasing
the number of motile cells in the vicinity of the oocyte signiﬁcantly
increased IVF success and reduced the incidence of fertilization defects
in men with sperm dysfunction (Tournaye et al., 2002). Thus, in the
potential target clinical population (men with sperm generally below
WHO 2010 (Cooper et al., 2010) thresholds of motility), there would
only need to be a relatively moderate increase in motility to potentially
have a noticeable clinical beneﬁt. If successful, this strategywould simplify
and increase access to treatment (Leﬁe`vre et al., 2007). Increasing
success rates of IUI and/or IVF would reduce dependence on ICSI and
have a substantial cost saving. For example, converting 10% of the
61 000 IVF/ICSI cycles done annually in the UK (HFEA, 2013) to
intervention-supported IUI would save up to £27.5 million per annum,
with proportionate savings worldwide.
The objective of this study was to systematically and comprehensively
screen a series of 43 commercially available compounds with reported
PDEI activity to identify key candidates that could be added to human
spermatozoa in vitro to enhance their motility. Using a two-stage ap-
proach, we have successfully identiﬁed several compounds that have
robust and effective stimulation of sperm motility (i.e. functional signiﬁ-
cancewith longevity and no toxicity) and, importantly, have a positive re-
sponse on patient samples. These compounds could be subjected to
further study for potential clinical use and/or chemically modiﬁed to
improve efﬁcacy. The experiments presented provide an exciting ﬁrst
step towards the clinical goal of robust and effective in vitro sperm cell
stimulation.
Materials andMethods
Overall experimental design
Weused a two-phased approach (Fig. 1). Phase 1 screened 43 commercially
available compounds with reported PDEI activity in order to identify lead
compounds that stimulate sperm motility (Fig. 2). These lead compounds
(n ¼ 6) progressed to Phase 2 which provided a comprehensive assessment
using a series of in vitro sperm function tests designed to determine if the com-
pounds could be of potential clincial value (see Mortimer et al., 2013). All
screening was performed blind. The codes to the compounds are presented
in Supplementary data, Table SI.
Ethical approval
Written consent was obtained from each patient in accordance with the
Human Fertilization and Embryology Authority (HFEA) Code of Practice
(version 8) under local ethical approval (08/S1402/6) from the Tayside
Committee of Medical Research Ethics B. Similarly, volunteer sperm
donors (healthy men randomly selected from the general public with no
known fertility problems) were recruited in accordance with the HFEA
Code of Practice (version 8) under the same ethical approval.
Study subjects
Semen samples were obtained from samples from healthy research donors
(with a normal sperm concentration and motility according to WHO 2010
criteria). These samples were used in Phase 1 and Phase 2 of the study.
Patient samplesused in Phase2were fromsubfertile patientswhounderwent
diagnostic investigations and/or treatment at the Assisted Conception Unit
(ACU), Ninewells Hospital, Dundee, Scotland.
Figure 1 Schematic diagram of overall experimental design: 43 com-
poundswere identiﬁed and selected at theDDU,University ofDundee.
Effects of compounds on the kinematic parameters of human spermato-
zoa were assessed using CASA. Compounds that have robust and ef-
fective stimulation on sperm motility were selected for further testing
(Phase 2) to determine their effect(s) on sperm function, including
experiments on patient samples.
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Semen samples
Semen samples from donors and patients were collected by masturbation
into a sterile plastic container after 2–3 days of sexual abstinence. The
samples were used for analysis after liquefaction of the semen at 378C for
30 min and within 1 h of production. Semen samples obtained from
patients were assessed for the semen proﬁle by clinical embryologists and
selected for IVF or ICSI according to clinical indications and semen quality.
For the latter, although not always, men with 1 × 106 progressively
motile cells post-preparation were allocated to IVF and those below this
limit were allocated to ICSI. The surplus of the clinical sample used in the
IVF or ICSI treatment process was used for analysis (Alasmari et al., 2013b).
Preparation and analysis of patient samples
In the ACU, commercially available media were used for sperm preparation.
The spermatozoa were separated from semen by density gradient centrifu-
gation (40%:80%) using PureSpermTM (Nidacon, Mo¨lndal, Sweden) diluted
with Quinn’s Advantage Medium with HEPES (SAGE In-Vitro Fertilization;
Pasadena, CA, USA). After centrifugation, the pellet was washed by centri-
fugation at 500g for 10 min in 4 ml of Quinn’s Advantage Medium with
HEPES. If the samples were assigned for IVF, following centrifugation, the
supernatantwas discardedandpelletwas resuspended inQuinn’sAdvantage
Fertilization medium. If the sample was allocated for ICSI, the cells were
washed and prepared in Quinn’s Advantage Medium with HEPES (Alasmari
et al., 2013a,b).
Chemicals
Compound(s) were purchased from Tocris Bioscience (Bristol, UK),
Sigma-Aldrich (Dorset, UK) or Santa Cruz Biotechnology (Heidelberg,
Germany) by the DrugDiscoveryUnit (DDU) at the College of Life Sciences
(University of Dundee, UK). The compounds were coded (#1–43 byDDU)
and tested for sperm function with an initial primary focus on spermmotility.
The codeswere brokenonce all experimentswere completed. In Phase 1, 43
compoundswere analysed in three independent experiments using 1, 10 and
100 mMﬁnal concentrations of compounds.Only the results for the 100 mM
experiments are reported.
Media and donor sperm preparation
All chemicalswerepurchased fromSigma-Aldrich. Twodifferentmediawere
used (i) not supporting sperm capacitation [non-capacitatingmedia (NCM)]:
1.8 mM CaCl2, 5.4 mM KCl, 0.8 mM MgSO4.7H2O, 116.3 mM NaCl,
1.0 mM NaH2PO4, 5.55 mM D-glucose, 2.73 mM sodium pyruvate,
41.75 mM sodium lactate, 25 mM HEPES and 3 mg/ml BSA; (ii) supporting
capacitation [capacitating media (CM)]: 1.8 mM CaCl2, 5.4 mM KCl,
0.8 mM MgSO4.7H2O, 116.3 mM NaCl, 1.0 mM NaH2PO4, 5.55 mM
D-glucose, 2.73 mM sodium pyruvate, 25 mM sodium lactate, 26 mM
sodium bicarbonate and 3 mg/ml BSA (see Alasmari et al., 2013a). In
Phase 1, semen samples were obtained from healthy donors and two differ-
ent sperm populations were isolated using a 40–80% discontinuous density
gradient procedure. Brieﬂy, 1 ml of semen was loaded after 30 min of lique-
faction at 378C on the top of a colloidal silica suspension (PureSpermTM)
made of 80 and 40% layered (2 ml each). The density gradient was centri-
fuged at 300g for 20 min. High-quality cells were in the 80% fraction and
the poor motility population was recovered at the interface of 40–80%, re-
spectively, called the 80 and 40% fractions. Both fractions were washed in
NCM by centrifugation for 5 min at 500g and the sperm pellet was
re-suspended using NCM or CM at 20 × 106 cells/ml. Sperm cells from
three to ﬁve different donors were pooled together after sperm preparation
in order to obtain enough cells to screen four to ﬁve compounds at the same
Figure2 Procedureperformed to screendifferent compounds in Phase1: samples from three to four donorswereused to isolate the40% fraction (poor
motility population) by density gradient centrifugation. Following spermpreparation, cells were pooled together and 100 ml was used to assess quantitative
sperm motility following 20 min incubation with 100 mM ﬁnal concentration of compound(s) in NCM.
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time, thus reducing variability. The ﬁrst screening was performed with NCM
as these are the conditions commonly used in clinics for IUI (Bjorndahl et al.,
2010). In Phase 1, the experiments weremainly performed on the 40% frac-
tions (spermcellswith poormotility),whichwereused as putative surrogates
for patient samples. Previous studies have suggested that sperm cells from
this fraction have a similar proﬁle in terms of motility, morphology and
DNA status to men with male infertility (O’Connell et al., 2003; Glenn
et al., 2007).
Motility assessment and compound(s)
treatment
Once the spermatozoawere isolated, theyweremixedwithDMSO (vehicle;
1% ﬁnal concentration) or with 1, 10 or 100 mMﬁnal concentrations of com-
pound(s). Sperm cells were incubated for various times at 378C (for cells in
NCM) or in a 5% CO2 humidiﬁed atmosphere (for cells in CM) and the mo-
tility was evaluated using a computer-assisted-sperm analysis (CASA)
[CEROS machine (version 12), Hamilton Thorne Research, Beverly, MA,
USA] attached to an external microscope. Sperm motion characteristics
were assessed under a negative phase contrast objective as previously
described (Alasmari et al., 2013a). System parameter settings for these ana-
lyses were 30 frames at 60 frames per second (Hz); minimum contrast 80;
minimum size 3 (pix); upper and lower gates of 0.39 and 1.4 for intensity;
and 0.85 and 4.24 for size and the default values for non-motile cells were
6 and 160 for size and intensity, respectively. A minimum of 16 data points
were used for tracking a cell. Spermatozoa with an average path velocity
.25 mm/s and 80% straightness are considered progressive, while those
with a curvilinear velocity (VCL) .150 mm/s, amplitude of lateral head dis-
placement.7.0 mmanddecrease in linearity [(straight line velocity/VCL) ×
100] (LIN) ,50% are deﬁned as hyperactivated cells. Spermatozoa were
examined in four-chamber slides of 20 mM deep (Vitrolife, Sweden). In
Phase 1, sperm motility was evaluated using a pool of three four semen
samples per treatment. After each treatment, aliquots were taken from each
pool and loaded on the chamber slides with 200 sperm cells analysed at
each sectionof the four-chamber slides. Thiswasperformedon three separate
occasions with different pooled samples (Fig. 2). In Phase 2, individual semen
samples were used.
Acrosomal status evaluation
Prepared sperm cells (as for donor sperm above) were incubated in the
absence or in the presence of compound (100 mM ﬁnal concentration) in
NCM for up to 5 h of incubation. The sample was divided into two where
one was incubated with 10 mM of calcium ionophore A23187 (Sigma) and
the other half was incubated with the vehicle (1% DMSO), both for 15 min
at 378C. Once complete, cells were smeared, dried onto microscope
slides, ﬁxed and permeabilized with 100% methanol and incubated at
room temperature for 30 min. The percentage of acrosome reacted cells
was evaluated by using ﬂuorescein– isothiocyanate conjugated Pisum
sativum lectin (PSA-FITC) as previously described (Bjorndahl et al., 2010).
Brieﬂy, smeared spermatozoa were incubated with PSA-FITC (100 mg/ml)
in the dark for 20 min. The slides were washed with Tris-buffered saline
(10 mMTris–HCl pH 7.4, 150 mMNaCl), mounted (Hydromount, Nation-
al Diagnostics) with cover slips and at least 200 cells were scored as ‘acro-
some intact’ or ‘acrosome reacted’.
Phosphatidyl translocation determined by
annexin V/propidium iodide
As an indicator of apoptosis, the translocation of PS from the inner to outer
leaﬂet of the sperm plasmamembranewas assessed by annexin V staining kit
(Martin et al., 2005). Brieﬂy, prepared sperm cells were incubated with or
without compound (100 mM) in NCM for 20 min. After 20 min of
incubation, cells were incubated with annexin-FITC (50 mg/ml)/propidium
iodide (100 mg/ml) in NCM and 20 ml of this sperm solution was mounted
on a microscope slide and viewed under UV excitation with FITC ﬁlters. A
minimum of 200 cells were scored per slide.
Penetration assay (Kremer test)
A modiﬁed Kremer tests using methyl cellulose (4000 cP: Sigma-Aldrich,
M0512) was used to assess sperm functional ability to penetrate into
viscous media as previously described (Ivic et al., 2002; Alasmari et al.,
2013b). Brieﬂy, sperm cells were previously treated with compound as
described above and glass tubes ﬁlled with methyl cellulose was placed ver-
tically in the sperm solution. Glass tubes (5 cm × 0.8 cm × 2 mm; Vitro-
com, Mountain Lakes, NJ, USA) were loaded with methyl cellulose by
capillary action and the tubes were incubated with the sperm cells at 378C
for 1 h 15 min. The number of sperm cells was scored at 1 cm. The results
are expressed as a penetration index [number of spermatozoa observed
with treatment/the number of spermatozoa without treatment (control)].
Removal of compoundafter 20 min incubation
The longevity of motility as a result of incubation with the compound was
tested following washing of the samples. This process was used to simulate
the clinical protocols where the compoundswould bewashed prior to insem-
ination (e.g. IUI) into the female tractoradditionof spermtotheoocytes in IVF.
Spermcellswithpoormotilitywere isolatedaspreviouslydescribed(seeFig.2)
and incubated with selected compounds for 20 min, then the samples were
washed (5 min at 300g). Samples were then examined for up to 300 min.
Statistical analysis
Signiﬁcance of differences between compound(s) was determined by
ANOVA using the statistical package PASW Statistics for Windows
(Version 18.0., SPSS, Inc., Chicago, IL, USA). The Fisher protected least sig-
niﬁcant difference test was conducted when the main effect was signiﬁcant
(P, 0.05) to determine which treatments were signiﬁcantly different. The
normal distribution was determined by Kolmogorov–Smirnov test and the
homogeneity of variance was tested by using the Levene statistical test. Mul-
tiple comparisons were analysed using the Tukey’s test. For the analysis of in-
dividual patient samples, an individual positive response for either % total or
% progressive motility was recorded when the values following compound
stimulation were noticeably different from control (basal) levels, i.e. when
the 2× standard deviations did not overlap.
Results
Phase 1 screened 43 commercially available compounds with reported
PDEI’s activity to identify lead compounds that stimulate spermmotility.
The selected candidates (n ¼ 6) progressed to Phase 2which provided a
more comprehensive assessment using a battery of in vitro sperm func-
tion tests.
Phase 1
The initial screening using the poor motility fraction from pooled donor
samples identiﬁed a number of compounds with a signiﬁcant effect on
motility (total and progressive motility) (Fig. 3A, Supplementary data,
Fig. S1). These were artiﬁcially classed as moderate (20–60% increase
in total motility) and strong effects (.60% increase in total motility)
(Supplementary data, Fig. S1). At the end of Phase 1, six compounds
(# 1, #26, #30, #36, #37 and #38) were identiﬁed to have a strong
effect on total and progressive motility and were chosen for further
evaluation in Phase 2 (Fig. 3A).
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Phase 2
Individual samples
Examination of the compounds on individual samples showed a signiﬁ-
cant increase in total and progressive motility for all compounds
(except #26 for total motility) (Fig. 3B). There was no signiﬁcant dif-
ference between the compounds regarding the effect on total or
progressivemotility (Fig. 3B). Similar signiﬁcant increases in total andpro-
gressive motility were observed compared with the pooled samples
in Phase 1 (compare Fig. 3A and B).
Penetration assay (Kremer test)
There were signiﬁcantly higher numbers of cells at 1 cm when sperm
were incubated in any of the six compounds compared with vehicle
control (Fig. 4). Cells incubated in compounds #26 and #38
showed a signiﬁcantly higher response than #1 and #36. Cell incu-
bated in compound #38 also showed a signiﬁcantly higher response
than those incubated in #30, whilst those incubated in compound
#37 showed no signiﬁcant differences compared with the other
compounds.
Figure 3 Effect(s) of compound(s) on sperm motility: spermatozoa with poor motility from the 40% fraction were treated for 20 min at 378C with
100 mM of compound. (A) Responses arbitrarily categorized into: strong responder (#1, #26, #30, #36, #37 and #38) and mild responder (#7, #13,
#15), where a 100% increase equals a 2-fold increase in motility compared with 1% DMSO negative control (i.e. if DMSO ¼ 15%, treatment ¼ 30%).
n ¼ 3 (three separate analysis of pooled sample), mean+ SEM (see Supplementary data, Fig. S1a–d for other compounds tested). The green line indicates
threshold for strong responder (≥60% increase), while the red line is the threshold for background.X-axis titlewith yellowcolour indicates themost prom-
ising compounds. (B) Effect(s) of selected compounds on percentage ofmotile and progressively motile cell under non-capacitating conditions (*P ≤ 0.05,
**P ≤ 0.001and ***P ≤ 0.0001 in comparisonwith control),n ¼ 6 (six different samples fromsix individuals),mean+ SEM. (C) Spermcellswere incubated
at 378C in a 5%CO2 humidiﬁed atmosphere for 3 h; theywere then treatedwith 100 mMof compound and left to incubate for 20 min at 378C in a 5%CO2
humidiﬁed atmosphere (*P ≤ 0.05, **P ≤ 0.001 and ***P ≤ 0.0001 in comparison with control), n ¼ 7 (seven different samples from seven individuals),
mean+ SEM.
Figure 4 Penetration of spermatozoa treated with compound into
viscous media: sperm cells from 40% fraction (poor motility population)
were treatedwithorwithout100 mMﬁnalconcentrationofcompound(s)
[1% DMSO-Control, 500 mM IBMX (3-isobutyl-1-methylxanthine)-
positive control].Treated cellswereallowed topenetrate intomethyl cel-
lulose solution for 1 h 15 min (Kremer test) (*P ≤ 0.05, **P ≤ 0.001 and
***P ≤ 0.0001 incomparisonwithcontrol),n ¼ 8 (eightdifferent samples
from eight individuals), mean+ SEM.
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AR and PS externalization
There was no signiﬁcant induction of the AR (P ¼ 0.6) or of PS external-
ization (P ¼ 0.6) after continuous incubation with any of the compounds
compared with vehicle controls (Supplementary data, Fig. S2).
Experiments in CM
Sperm cells incubated in capacitating conditions with each of the com-
pounds showed a signiﬁcant increase in % total and % progressive motil-
ity (n ¼ 7 Fig. 3C) compared with controls. The increase was
comparable to that in cells incubated under non-capacitating conditions
(n ¼ 6 samples; compare Fig. 3B and C).
Longevity of effect following continuous incubation
Phase 1 tested the motility after a 20 min incubation period. When
sperm samples were continuously incubated with compounds over a
longer period of time (up to 180 min), there was generally a signiﬁcantly
higher total andprogressivemotility comparedwith the control (Table I).
Speciﬁcally, for total motility, cells incubated in compounds #37 and
#38 were signiﬁcantly different from the controls at each time point
(Table I). Cells incubated in compound #36 were signiﬁcantly different
from the control at T20, T60, T90 and T120. Cells incubated in com-
pounds #26 and #30 were signiﬁcantly different from the control at
T20, T60, T90. Cells incubated in compound #1 were not consistently
signiﬁcantly different over time. Speciﬁcally for progressive motility,
cells incubated in all compounds were signiﬁcantly different from the
control at each time point (Table I).
Removal of compounds
Following incubation for 20 min, the samples were washed (to simulate
removal of compound for clinical use prior to, for example, IUI) and incu-
bated for up to 300 min. There was still a signiﬁcantly higher total and
progressively motility compared with controls at the end of incubation
with each compound (Table II).
Speciﬁcally for total motility, cells incubated in compound #1, #26,
#36, #37 and #38 showed a signiﬁcant increase in comparison with
the control, at each time point except at W20 (compound #38) and
W20 and W60 (compound #1). There was no signiﬁcant difference in
cells incubated in compounds before (T20) and after wash off (i.e.
W0-W300). Cells incubated in compound #30 did not show a consist-
ent signiﬁcant difference over time.
For progressivemotility, cells incubatedwith all compounds showed a
signiﬁcant increase at T20. After washing, cells incubated in compounds
#36 and#37 showed a signiﬁcant increase at each time point. Cells incu-
bated in compound#30, however, donot showany signiﬁcant difference
comparedwith control. Those incubated in compound#1werenot con-
sistently signiﬁcantly different over time.
Patient samples prepared in NCM
In total, 23patientswereanalysed in this category (Table III). Thepatients
were attending for either routine diagnostic andrology assessment or
IVF/ICSI and a portion of their semen sample was examined following
density gradient centrifugation (as above) and analysed. It was not
always possible to compare all six compounds in a single clinical
sample due to limitations in the number of sperm available. However,
whilst each patient is an individual, there are some general trends. In
3/8 patients with high total motility (WHO normal) there was no re-
sponse (or a negative response) to the compounds (#1, #26, #30,
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#37 and#38). Therewas a noticeable numberwho showed a signiﬁcant
increase in progressive motility to some, but not all compounds. In con-
trast, in patients with low progressive motility, there were a higher pro-
portion of patient samples that responded positively compared with
those in the normal category. In patient samples with low total motility
and low progressive motility, there was a positive response, either by
an increase in total motility and/or progressive motility to some, but
not all compounds. In this category, only one patient showed no re-
sponse to any compound (sample ID: 760).
IVF patients samples prepared in Quinn’s Advantage Fertilization
medium
Therewere 32 patients analysed in this category (Table IV). The patients
were attending for IVF and a portion of their density gradient-prepared
sample that was used for treatment was obtained for research purposes
and analysed. Again, it was not always possible to compare all six com-
pounds due to limitations in the number of sperm available in a clinical
sample. As expected, the majority of these patients had normal total
and progressivemotility (27/32 Table IV).Whilst each patient is an indi-
vidual, there are some general trends: compounds #37, #38 and #26
were the most effective in increasing the percentage of total motile
cells [#26 and #37 (20/32) ¼ 63% and #38 (17/27) ¼ 63% of
patients]. As for samples in NCM, the most signiﬁcant effects were in
samples with borderline/low motility.
ICSI patients samples prepared in Quinn’s Advantage Medium with
HEPES
There were only 16 patients in this category and very small sample
volumes were obtained and so the analysis is limited (Table V).
However, sperm cells incubated in compound #26 or #37 showed, in
all but one case (15/16; 13/14, respectively), an increase in progressive
motility. In 14/16 and 11/14 cases, therewas an increase in totalmotility
for compounds #26 and #37, respectively. For compound #38, 9/11
cases showed an increase in total or progressive motility.
Discussion
Using a two-stage comprehensive approach, we have successfully
identiﬁed several compounds that have robust and effective stimulation
of sperm motility, are non-toxic, initiate a functional improvement
as judged by Kremer testing and importantly have a positive response
on a signiﬁcant proportion of patient samples prepared under clinical
conditions.
This study used a two-phase strategy. In Phase 1, 43 commercially
available compounds with reported PDEI activity were screened for
their effects on sperm motility using CASA. Pooled samples from three
to four different donors were utilized to reduce variability and increase
the number of cells available for simultaneous examination of multiple
compounds (usually three to ﬁve in each run). Cells in the 40% fraction
(those with poor motility) were used as putative surrogates for patient
samples. Previous studies have suggested that these cells have a similar
proﬁle, in terms of motility, morphology and DNA status, to men with
sperm dysfunction/male infertility (O’Connell et al., 2003; Glenn et al.,
2007). The ﬁrst screening was performed with NCM, as these are the
conditions normally used for IUI (Bjorndahl et al., 2010). Moreover, an
incubation time of 20 min was designed to ﬁt with clinical procedures
for sperm preparation. In general, consistent results on sperm motility
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were obtained. In Phase 1, the effects of the six leading compoundswere
determined using pooled samples. Experiments on individual samples
then showed a similar proﬁle of results to pooled samples, and,
notably showed a signiﬁcant increase in both total and progressivemotil-
ity (Fig. 3A and B; Supplementary data, Fig. S1). Additionally, consistent
stimulationof total andprogressivemotilitywereobtainedwhen the cells
were incubated under capacitating conditions (Fig. 3C).
Theobjective of Phase 1was to allowa large numberof compounds to
be screened relatively efﬁciently in order to identify potential hit targets
for further study. Phase 2 consisted of amore detailed assessment based
around guidelines for the testing of compounds that can potentially be
considered safe for clinical use (Mortimer et al., 2013). Phase 2 involved
sperm function testing with a view to the use of the compounds in ART,
e.g. IUI. Modiﬁed Kremer testing demonstrated that the stimulation in
motility was also of functional beneﬁt, i.e. higher numbers of cells pene-
trated the viscousmedia. Importantly, the compounds did not appear to
have a signiﬁcant negative effect as there was no signiﬁcant induction of
the AR (Supplementary data, Fig. S2) or PS exposure (Supplementary
data, Fig. S2). This is consistent with the ﬁnding of motility maintenance
over a signiﬁcant time course, evenwith continuous incubation (Table I).
Whilst the six key compounds selected for Phase 2 had positive effects,
thereweredifferences in the efﬁcacy suggesting fewer lead candidates for
future clinical use. For example, compounds #26, #37 and #38 had the
most signiﬁcant effect on Kremer testing which is broadly consistent, at
least for compounds #37 and #38 with the positive effect on motility
over time (Table I). Clinical use of the compounds would involve
washing and effective removal prior to use. Table II demonstrates that
stimulationof totalmotilitywasmaintainedover time; however, progres-
sivemotility was not consistently affected using compounds#1 and#30.
Continual incubation (Table I) suggests that the positive effect on total
motility of compounds #1 and #26 and #30 were not maintained
throught incubation. For progressive motility, particular stimulation
with compounds #38 and #37 was observed (Table I).
The fundamental clinical aim is to translatewhat happens in an experi-
mental model to effects in patient samples. To address this, we tested a
spectrum of diagnostic and treatment samples under both non-
capacitating and capacitating conditions (Tables III–V). In general, in
samples with good motility, e.g. IVF, there was a minimal effect on
totalmotility but, in somecases, a noteable effect onprogressivemotility.
In contrast, in samples with lower motility, there was a signiﬁcant effect
.................. .................. .................. .................. .................. ..................
.............................................................................................................................................................................................
Table III Summary matrix of patient samples (NCM) treated with selected compound(s).
Sample ID WHO category #1 #26 #30 #36 #37 #38
TM PM TM PM TM PM TM PM TM PM TM PM
Decreasing total motility
721 WHO normal   — — — — — — — — — —
710 WHO normal — —  —  — —   —  —
716 WHO normal —  —  —  —  —  — 
663 WHO normal —           
734 WHO normal — — — — — — — — — —
736 WHO normal — — — — — — — — — —
774 WHO normal —  —  —  — — —  — 
717 WHO normal — — —  —  —  — — — —
557 Borderline  —          
PT01 Borderline —    — 
723 Borderline —      — 
784 Borderline —      —    — 
786 Borderline       —     
642 Borderline        
653 Borderline —           
769 Borderline — —     —  —  — 
760 Low TM and PM — — — — — — — — — — — —
782 Low TM and PM     — 
708 Low TM and PM            
725 Low TM and PM — —  — — — — —  —  —
709 Low TM and PM  
761 Low TM and PM  
729 Low TM and PM  
, Signiﬁcant increase; —, no change; , signiﬁcant decrease; empty cell, drug was not used in the experiment.
WHO normal: WHO normal limits for total motility (40%) and progressive motility (32%), Borderline: borderline motility, low TM and low PM: both total and progressive motility are
below the WHO normal limit. No entry means compound is not tested. Signiﬁcance means SD do not overlap (TM: total motility, PM: progressive motility).
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on both total and progressivemotility. These clinical data give some indi-
cations as to the possible therapeutic use and effectiveness. Generally,
there appears to be limited beneﬁt for samples with good motility, as
expected and consistent with previous data using PTX (Nassar et al.,
1999). In cells incubated under non-capacitating conditions 15/23 and
17/23 of the samples responded to compound #26 with regard to
total and progressive motility. From the limited data available, com-
pounds #1 and#30were less effective. In samples incubated under cap-
acitating conditions (Table IV), compounds #37, #38 and #26 were the
most effective in increasing the percentage total motile cells (63% of
samples) and, as for samples in NCM, the most signiﬁcant effects were
in samples with borderline/low motility. Only relatively few ICSI
sampleswereexamined (TableV); however, in theoverwhelmingmajor-
ity of cases, cells incubated in compounds #26, #37 and #38 showed an
increase in progressive motility and total motility.
For practical purposes, three concentrations were adopted in Phase 1
using doses of 1, 10 and 100 mM. The objective was to determine which
concentration was the most effective under these conditions (non-
capacitating conditions with cells in the 40% fraction). Concentrations
of 1 and 10 mM did have pro-motility effects, in some cases, but it was
.................. .................. .................. .................. .................. ..................
.............................................................................................................................................................................................
Table IV Summarymatrixof IVFpatient samples [Quinn’sAdvantagewFertilization (HTF)Medium] treatedwith selected
compound(s).
Sample ID WHO category #1 #26 #30 #36 #37 #38
TM PM TM PM TM PM TM PM TM PM TM PM
Decreasing total motility
943 WHO normal — —  —  —  — — —  —
1232 WHO normal — — — — — — —  — 
1308 WHO normal  —  — — —  — — 
997 WHO normal          
947 WHO normal —  —  —  — — — — — 
1212 WHO normal    —  — — —  —
939 WHO normal —    —  — —   — —
985 WHO normal — — — — — — — — — — — —
1020 WHO normal  —  —
944 WHO normal — —  — — — — —  —  —
1307 WHO normal  —    —  —  —
872 WHO normal — — — — — — —  —  — 
986 WHO normal — — — — —  — — —  — 
1227 WHO normal          
1018 WHO normal    —
1234 WHO normal      —    
1290 WHO normal  —    —  —  —
1298 WHO normal          
911 WHO normal        —  —  —
865 WHO normal — — — — — — — — — — — —
1302 WHO normal   — — — — — —  
867 WHO normal — — — —   — —    —
919 WHO normal  — — —
992 WHO normal — — — — — — — —
937 WHO normal       —     
877 WHO normal — — —  —  — —    
1273 Borderline          
1037 Borderline — —  —
1019 WHO normal  —  —
949 Borderline — — —  — — — —    
991 Borderline   — —    
891 Low TM and PM      
, Signiﬁcant increase; — no change; , signiﬁcant decrease; empty cell, drug was not used in the experiment.
WHO normal: WHO normal limits for total motility (40%) and progressive motility (32%), borderline: borderline motility, low TM and low PM: both total and progressive motility are
below the WHO normal limit. No entry means compound is not tested. Signiﬁcance means SD do not overlap (TM: total motility, PM: progressive motility).
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verymuch less (data not shown) and as such Phase 2 only used PDEIs at a
concentrationof 100 mM.For someof the compounds tested, 100 mMis
much greater than the reported IC50 (e.g compound #1), whilst for
others (e.g. compound #26) it is comparable (see Supplementary
data, Table SII). What is interesting is that the reported IC50 for a
number of compounds varies remarkably perhaps because some are
generated using puriﬁed recombinant enzymes and others on a wide
variety of different cell types (Supplementary data, Table SII). For sperm-
atozoa there are no available data; there is no information on what con-
centration of compound enters the sperm cytoplasm,whether there are
pumps effectively making high external concentrations necessary, the
speciﬁcity of the sperm PDE complex(s) or which complexes are
present (see below). Preliminary experiments on the three most pro-
mosing candidates (compounds #26, #37 and #38) utilized concentra-
tions from 0.5 to 100 mM to examine a potential concentration effect on
motility and kinematic parameters. For compound#26, progressivemo-
tility was signiﬁcantly stimulated at 20–100 mM (in keeping with the IC50
for other cells), whereas progressivemotility was signﬁicantly stimulated
at 1–100 mM for compound #37 and at 0.5–100 mM for compound
#38, both of which are within the ranges of the IC50 for other cell
types (see above and Supplementary data, Figs S3–S5, respectively).
Surprisingly, in viewof the plethora of information available on PDEs in
other cells, there is a remarkable paucity of studies on the identity, loca-
tion and nature of PDEs in the human spermatozoon (Conti and Beavo,
2007; Houslay, 2009). The measurement of sperm PDE activity in the
presence of inhibitors for PDE-1 (8-MeO-IBMX) (Fisch et al., 1998),
PDE-4 (RS 25344) (Fisch et al., 1998), PDE-3 (milrinone) (Leﬁe`vre
et al., 2002), PDE-5 (sildenaﬁl) and stimulators for PDE-1 (calcium/
CaM) (Leﬁe`vre et al., 2000, 2002) suggests that these PDEs are
present in human spermatozoa, although PDE-5 is present at very low
levels. mRNA transcripts of PDEs have been detected (Richter et al.,
1999) but very few studies examine localization (Leﬁe`vre et al., 2002)
and there are minimal data on protein expression. In fact, proteomic
studies of human sperm reveal a paucity of PDE in spermatozoa (Baker
et al., 2013; Wang et al., 2013). There are no studies examining the
role of defective PDEs in sperm dysfunction, e.g. aberrant expression.
In view of the high concentrations of compounds used in this study the
speciﬁcity of effect on PDEs is also uncertain. Other biochemical path-
ways could be affected and as such we do not know if the biological
effect is via PDE and/or another mechanism. Notwithstanding the clin-
ical end-point is real: there are signiﬁcant changes in movement
without an adverse effect on sperm function; however, more detailed
biochemical studies are required to ascertain themechanism(s)of action.
In viewof the above it is perhaps not surprising that of the six key com-
pounds identiﬁed as potential clincial candidates (dipyridamole, ibudilast,
8-MeO-IBMX, etazolate hydrochloride, papaverine and toﬁsopam)
there is a noteable lack of data on human sperm.No information is avail-
able on dipyridamole, ibudilast or toﬁsopam. Etazolate hydrochloride,
which is reported as a selective PDE-4 inhibitor (as SQ20009), increases
cAMP in hamster sperm (Mrsny et al., 1984) and phosphorylation of
membrane proteins (presumably as part of capacitation) in humans
(Huacuja et al., 1977), although there are no data on motility.
8-MeO-IBMX, reported as a speciﬁc inhibitor of calmodulin-sensitive
cyclic GMP PDE, has been used in mice fertilization studies (Baxendale
.................. .................. .................. .................. .................. ..................
.............................................................................................................................................................................................
Table V Summary matrix for ICSI patient samples (Quinn’s AdvantagewMedium with HEPES) treated with selected
compound(s).
Sample ID WHO category #1 #26 #30 #36 #37 #38
TM PM TM PM TM PM TM PM TM PM TM PM
Decreasing total motility
1160 WHO normal — — — —  
1163 WHO normal        
1213 WHO normal      
1251 WHO normal      
1309 WHO normal          
873 WHO normal — —   — — — — — — — —
1154 Borderline   —     
1236 Borderline          
1233 Borderline          
1162 Borderline —  —  —  — 
1150 Low TM and PM   — — —   —
1183 Low TM and PM      
1038 Low TM and PM    
1261 Low TM and PM    
1301 Low TM and PM      
1257 Low TM and PM        
, Signiﬁcant increase; — no change; , signiﬁcant decrease; empty cell, drug was not used in the experiment.
WHO normal: WHO normal limits for total motility (40%) and progressive motility (32%), borderline: borderline motility, low TM and low PM: both total and progressive motility are
below the WHO normal limit. No entry means compound is not tested. Signiﬁcance means SD do not overlap (TM: total motility, PM: progressive motility).
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and Fraser, 2005) but there are no reports of effects on the motility of
human spermatozoa. Papaverine, reported as a PDE-10A inhibitor,
has been used at a concentration of 500 mM to increase cyclic nucleo-
tides and mimic the effects of capacitation in human sperm. After
5 min of incubation, therewas an increased calcium response to proges-
terone (Torres-Flores et al., 2008). Papaverine has also been used to
mimic capacitation changes by modulating the cAMP pathway in boars
(Harrison, 2004) and guinea pig sperm (Hunnicutt et al., 2008).
In conclusion, we have successfully identiﬁed several compounds that
have robust and effective stimulation of spermmotility, are non-toxic to
the cells, initiate a functional improvement as judged by Kremer testing
and importantly have a positive response on a signiﬁcant proportion of
patient samples under clinical conditions of treatment. Ibudilast, papa-
verine and toﬁsopam appear to be very promising candidates but
further experiments are still necessary to establish safety and clinical
effectiveness, e.g. IVF and/IUI trials. There are signiﬁcant challenges
with screening for the effects of a large number of compounds on
human spermatozoa. CASA is not well suited to traditionally high-
throughput screening. In the long term, if signiﬁcant progress is to be
made in understanding sperm function, there is a genuine need to
develop a high-throughput assaywhichwould enable the rapid screening
of thousands of compounds.
Supplementary data
Supplementarydata areavailable athttp://humrep.oxfordjournals.org/.
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